Funds of $35M were secured by Field Medical for advancement of their PFA system.
In a significant development for the cardiac medical device industry, Field Medical, a California-based company based in Cardiff-by-the-Sea, has raised $35 million in Series B funding to support the initiation of its pivotal VERITAS trial for its pulsed field ablation (PFA) system targeting ventricular tachycardia (VT). This funding round was led by BioStar Capital and Cue Growth, with existing strategic investors also participating.
The announcement comes after promising pilot data presented at the 2025 Heart Rhythm Society meeting, demonstrating progress towards pivotal readiness. The funds will be used to support the start of the pivotal Veritas trial, further the development of the FieldForce Ablation System, and expand the company's clinical and regulatory capabilities.
Ventricular tachycardia, an irregular heart rhythm that can lead to sudden death, remains an underpenetrated market with unmet clinical needs. Dr. Steven Mickelsen, Field Medical's CEO and an electrophysiologist, emphasized the urgency to address this gap with a next-generation PFA therapy designed for speed and precision in high-risk VT patients.
Field Medical's innovative approach to treating VT has garnered support from industry leaders. Louis Cannon, a physician and the founder and senior managing director of BioStar Capital, believes that Field Medical's technology brings real innovation and urgency to a difficult challenge in cardiology.
Physicians have already embraced PFA to treat Atrial Fibrillation (AFib), a common arrhythmia that increases stroke risk. In fact, Medtronic and Boston Scientific brought the first PFA systems for AFib to market in late 2023 and early 2024, respectively. Johnson & Johnson and Abbott also sell PFA devices, with Abbott expecting FDA approval for its Volt system in 2026.
The latest financing round for Field Medical brings the total funds raised to date to $75 million. This funding will be instrumental in preparing for the pivotal trial and bringing Field Medical's cardiac ablation technology for VT treatment one step closer to market.
Sources: [1] Susan Kelly, "Field Medical raises $40M for PFA in ventricular tachycardia", MedTech Dive, 23 April 2025. [2] Susan Kelly, "Steven Mickelsen, Farapulse founder, eyes next frontier in pulsed field ablation", Cardiac Rhythm News, 4 March 2025.
- The latest news in health-and-wellness technology revolves around Field Medical's innovative cardiac device, the pulsed field ablation (PFA) system, designed for ventricular tachycardia (VT) patients.
- Artificial intelligence (AI) might play a crucial role in analyzing patient data during Field Medical's pivotal VERITAS trial, contributing to the advancement of science in the medtech industry.
- As the company gears up for the VERITAS trial, collaboration with industry leaders like BioStar Capital and Cue Growth is expected to strengthen Field Medical's clinical and regulatory capabilities, ensuring the safety and success of their medical devices.
- In the race to address unmet clinical needs in the underpenetrated ventricular tachycardia market, Field Medical's next-generation PFA therapy seeks to provide speed and precision while ensuring the highest levels of FDA safety standards.
- The medical device industry is witnessing an accelerated shift towards pulsed field ablation (PFA) systems, as companies like Medtronic, Boston Scientific, Johnson & Johnson, and Abbott have already introduced their PFA devices for Atrial Fibrillation (AFib) treatment, and Abbott anticipates FDA approval for its Volt system in 2026.
- With the successful completion of their pivotal trial and the approval of their cardiac ablation technology, Field Medical could revolutionize the treatment of ventricular tachycardia, making a significant contribution to the field of cardiology.
- Technology continues to play a role in enhancing research, as the results of Field Medical's clinical trials will potentially pave the way for new treatment options and further advancements in the medtech and healthcare sectors.
